The proteasome, a new target for cancer therapy

Onkologie

Volumn 25, Issue 6, 2002, Pages 534-539

  Gillessen, Silke ^a   Groettrup, M ^a   Cerny, T ^a  

^a Kantonsspital St Gallen ^*

Author keywords

Combination treatment; Proteasome inhibitor; Ubiquitin proteasome pathway

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GROWTH FACTOR; PROTEASOME; PROTEIN INHIBITOR; REGULATOR PROTEIN; UBIQUITIN;

ANOREXIA; APOPTOSIS; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE; CELL DIFFERENTIATION; CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; FATIGUE; FEVER; HUMAN; LUNG CANCER; MELANOMA; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; PERIPHERAL NEUROPATHY; RASH; REVIEW; SENSITIZATION; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CLINICAL TRIALS; CYSTEINE ENDOPEPTIDASES; DRUG EVALUATION; HUMANS; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION;

EID: 0036983124     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068624     Document Type: Review

References (52)

1. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik H, Huber R: Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 1997;386:463-471.
2. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R: Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science 1995;268:533-539.
3. Stock D, Ditzel L, Baumeister W, Huber R, Lowe J: Catalytic mechanism of the 20S proteasome of T. acidophilum revealed by X-ray crystallography. Cold Spring Harb Symp Quant Biol 1995;60:525-532.
4. Nussbaum AK, Dick TP, Keilholz W, Schirle M, Stevanovic S, Dietz K, Heinemeyer W, Groll M, Wolf D, Huber R, Rammensee HG, Schild HJ: Cleavage motifs of the yeast 20S proteasome β subunits deduced from digest of enolase. Proc Natl Acad Sci USA 1998;95:12504-12509.
5. Groettrup M, Schmidtke G: Selective proteasome inhibitors: Modulators of antigen presentation. Drug Discov Today 1999;4:63-71.
6. Omura S, Fujioto T, Otoguro K, Matsuzaki K, Moriguchi R, Tanake H, Sasaki Y: Lactacystin, a novel microbial metabolite. Omdicudes neuritogenesis of neuroblastoma cells. J Antibiot 1991;44:113-118.
7. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL: Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995;268:726-731.
8. Craiu A, Gaczynska M, Akopian T, Grann CF, Fenteany G, Goldberg AL, Rock KL: Lactacystin and clasto-lactacystin beta-lactone modify multiple preteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 1997;272:13437-13445.
9. Fenteany G, Standaert RF, Reichard GA, Corey EJ, Schreiber SL. A beta-lactone related to lactacystin induces neurite outgrowth in a neuroplastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc Natl Acad Sci USA 1994;91:3358-3362.
10. Lin KL, Baraban JM, Ratan RR: Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration. Cell Death Differ 1998;5:577-583.
11. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchl H: Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 1995;217:1070-1077.
12. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA: Proteasomes play an essential role in thymocyte apoptosis. EMBO J 1996;15:3835-3844.
13. Sadoul R, Fernandez PA, Quiquerez AL, Martinou I, Maki M, Schroter M, Becherer JD, Irmler M, Tschopp J, Martinou JC: Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J 1996;15:3845-3852.
14. Cerundolo V Benham A, Braud V, Mukherjee S, Gould K, Macino B, Neefjes J, Townsend A: The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur J Immunol 1997;27:336-341.
15. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL: Inhibitors of the proteasome block the degradaton of most dell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-771.
16. Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S: Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem 1996;119:572-576.
17. Harding CV, France J, Song R, Farah JM, Chatterjee S, Iqbal M, Siman R: Novel dipeptide aldehydes are proteasome inhibitors and block the MHC-I antigen-processing pathway. J Immunol 1995;155:1767-1775.
18. Figueiredo-Pereira ME, Chen WE, Yuan HM, Wilk S: A novel chymotrypsin-like component of the multicatalytic proteinase complex optimally active at acidic pH. Arch Biochem Biophys 1995;317:69-78.
19. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J: The Proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-2645.
20. André P, Groetrupp M, Klenerman P, de Giuli R, Booth BL Jr, Cerundolo V, Bonneville M, Jotereau F, Zinkernagel RM, Lotteau V: An Inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation and T cell responses. Proc Natl Acad Sci USA 1998;95:13120-13124.
21. Adams J: Development of the proteasome inhibitor PS-341. Oncologist 2002;7:9-16.
22. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622.
23. Adams J: Proteasome inhibition in cancer: Development of PS-341. Semin Oncol 2001;28:613-619.
24. Dulic V, Kaufmann W, Wilson S: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1013-1023.
25. King R, Deshaies R, Peters J: How proteolysis drives the cell cycle. Science 1996;274:1652-1659.
26. Pagano M, Tam S Theodoras A: Role of the ubuquitin-ptoeasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685.
27. Wu Y, Luo H, Kanaan N, Wu J: The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J Cell Biochem 2000;76:596-604.
28. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-B. J Clin Invest 2001;3:241-246.
29. Sunwoo J, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-1428.
30. Adams J: Proteasome inhibition: A novel approach to cancer therapy. Trends Mol Med 2002;8 (Suppl): S49-S54.
31. Adams J, Palombella VJ, Elliott P: Proteasome inhibition: A new strategy in cancer treatment. Invest New Drugs 2000;18:109-121.
32. Frankel A, Elliott SMP, Adams J, Kerbel RS: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000;6:3719-3728.
33. Drexler HC: Activation of the cell ceath program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997;94:855-860.
34. Masdehors P, Omura S, Bérak HM, Mentz F, Cosset JM, Dumont J, Magdelénat H, Delic J: Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystine. Br J Haematol 1999;105:752-757.
35. Wang C, Cusack J, Liu R, Baldwin A: Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-B. Nat Med 1999;5:412-417.
36. Cusack J, Liu R, Houston M, Abendroth K, Elliott P, Adams J, Baldwin A: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-B inhibition. Cancer Res 2001;61:3535-3540.
37. Pajonk F, Pajonk K, McBride WH: Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 2000;47: 1025-1032.
38. Bold R, Virudachalam S, McConkey D: Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;100:11-17.
39. Shah S, Potter M, McDade T: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82: 110-122.
40. Tan C, Waldmann TA: Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukaemia. Cancer Res 2002;15:1083-1086.
41. Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL, Magdelenat H: The proteasome inhibitor lactacystin induces apoptosis and sensitzes chemo-and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-a-initiated apoptosis. Br J Cancer 1998;77:1103-1107.
42. Russo S, Tepper J, Baldwin A: Enhancement of radiosensitivity by proteasome inhibition: Implications for role of NF-B. Int J Radiat Oncol Biol Phys 2001;50:183-193.
43. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-3076.
44. Gatto S, Scappini B, Verstovsek S, Milella M, Onida F, Ball G, Kantarjian H, Keating M, Cortes J, Beran M: In vitro effects of PS-341 alone and in combination with STI571 in bcr-abl positive cell lines both sensitive and resistant to STI571. Blood 2001;98:101a.
45. Goldberg AL, Rock K: Not just research tools - proteasome inhibitors offer therapeutic promise. Nat Med 2002;8:338-340.
46. Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH: Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 2002;109:671-679.
47. Luo H, Wu Y, Qi S, Wan X, Chen H, Wu J: A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001;72:196-202.
48. Ryan D, Eder J, Winkelmann J, Lynch T, Supko J, Appleman L, Fidias P, Enzinger P, Zhu A, Kinchla N, Esseltine D, Baldwin A, Elliott P, Adams J, Kauffman M, Schenkein D, Cusack J: Pharmacokinetic and pharmacodynamic phase I study of PS-431 and gemcitabine in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002;21:95a.
49. Iqbal S, Lenz HJ, Groshen S, Wei Y, Gandara D, Lara P, Gumerlock P, Doroshow J, Przemyslaw T, Synold T: Phase I study of PS-341 in combination with 5-FU/LV in solid tumors. Proc Am Soc Clin Oncol 2002;21:93a.
50. Thomas J, Arzoomanian R, Alberti D, Geiger P, Marnocha R, Tutsch K, Dresen A, Volkman J, Binger K, kolb M, Feierabend C, Black S, Hampton K, Wilding G: A phase I and pharmacodynamic study of the proteasome inhibitor PS-341 in combination with doxorubicin. Proc Am Soc Clin Oncol 2002; 21:93a.
51. Richardson P, Berenson J, Irwin D, Jagannath S, Traynor A, Rajkumar V, Alsina M, Kuter D, Srkalovic G, Siegel D, Barlogie B, Alexanian R, Orlowski R, Esseltine D, Kauffman M, Adams J, Schenkein D, Anderson K: Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood 2001;98:774a.
52. Richardson P, Barlogie B, Berenson J, Traynor A, Singhal S, Jagannath S, Irwin D, Rajkumar V, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski R, Kuter D, Limentani S, Esseltine D, Kauffman M, Adams J, Schenkein D, Anderson K: Phase II study of the proteasome inhibitor PS-341 in multiple myeloma (MM) patients with relapsed/refractory disease. Proc Am Soc Clin Oncol 2002;21:11a.